

ICP Pay for Performance - HEDIS 2013 1/1/2012 to 12/31/2012

| Measure | State Baseline Rate | QISMC Goal | Aetna | | | | Illinicare | | | |
|--|---------------------|------------|------------|--------------------------|----------------|-------------------|-----------------|--------------------------|----------------|-------------------|
| | | | Aetna Rate | Difference from Baseline | Overall Result | QISMC Goal Status | IlliniCare Rate | Difference from Baseline | Overall Result | QISMC Goal Status |
| Follow-up After Hospitalization for Mental Illness (FUH) - 30 day follow-up | 55.42% | 59.88% | 44.03% | -11.39% | Declined | Not Met | 40.90% | -14.52% | Declined | Not Met |
| Annual Dental Visit (ADV) Total - DD Population | 36.01% | 42.41% | 38.94% | 2.93% | Improved | Not Met | 28.12% | -7.89% | Declined | Not Met |
| Comprehensive Diabetes Care (CDC) The CDC measure requires a Goal Status of MET for 2 of #1-3, and 1 of #4-5 | | | | | | | | | | |
| 1. HbA1c Testing | 77.13% | 79.42% | 83.39% | 6.26% | Improved | Met | 79.69% | 2.56% | Improved | Met |
| 2. Nephropathy Monitoring | 75.42% | 77.88% | 80.47% | 5.05% | Improved | Met | 82.78% | 7.36% | Improved | Met |
| 3. LDL-C Screening | 75.63% | 78.07% | 80.84% | 5.21% | Improved | Met | 75.50% | -0.13% | Declined | Not Met |
| 4. Statin Therapy (80% of Eligible days) | 40.85% | 46.77% | 41.21% | 0.36% | Improved | Not Met | 38.32% | -2.53% | Declined | Not Met |
| 5. ACEI / ARB Therapy (80% of Eligible days) | 38.38% | 44.54% | 40.40% | 2.02% | Improved | Not Met | 38.10% | -0.28% | Declined | Not Met |
| Congestive Heart Failure (CHF) The CHF measure requires a Goal Status of MET for 2 of #1-3 | | | | | | | | | | |
| 1. ACEI / ARB Therapy 80% of the Time | 32.40% | 39.16% | 44.61% | 12.21% | Improved | Met | 36.48% | 4.08% | Improved | Not Met |
| 2. Beta Blockers 80% of the Time | 30.40% | 37.36% | 68.90% | 38.50% | Improved | Met | 78.70% | 48.30% | Improved | Met |
| 3. Diuretics 80% of the Time | 34.47% | 41.02% | 42.65% | 8.18% | Improved | Met | 42.86% | 8.39% | Improved | Met |
| Coronary Artery Disease (CAD) The CAD measure requires a Goal Status of MET for 2 of #1-4 | | | | | | | | | | |
| 1. Cholesterol Testing | 76.01% | 78.41% | 77.52% | 1.51% | Improved | Not Met | 74.72% | -1.29% | Declined | Not Met |
| 2. Statin Therapy 80% of the Time | 42.74% | 48.47% | 45.75% | 3.01% | Improved | Not Met | 43.38% | 0.64% | Improved | Not Met |
| 3. ACEI / ARB Therapy 80% of the Time | 36.59% | 42.93% | 40.88% | 4.29% | Improved | Not Met | 37.69% | 1.10% | Improved | Not Met |
| 4. Persistence of Beta-Blocker Treatment After a Heart Attack (PBH) | 35.00% | 41.50% | 86.00% | 51.00% | Improved | Met | 87.80% | 52.80% | Improved | Met |
| Pharmacotherapy Management of COPD Exacerbation (PCE) The PCE measure requires a Goal Status of MET for 2 of #1-3 | | | | | | | | | | |
| 1. Systemic corticosteroid dispensed cortocosteriod within of 14 days of the event | 62.08% | 65.87% | 69.97% | 7.89% | Improved | Met | 72.37% | 10.29% | Improved | Met |
| 2. Bronchodilator dispensed within 30 days of the event | 78.13% | 80.32% | 89.47% | 11.34% | Improved | Met | 90.79% | 12.66% | Improved | Met |
| 3. Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)* | 29.67% | 36.70% | NA | NA | NA | NA | NA | NA | NA | NA |
| Ambulatory Care Follow-up Measures | | | | | | | | | | |
| Ambulatory Care Follow-up with a Provider within 14 Days of Emergency Department Visit | 40.25% | 46.23% | 40.92% | 0.67% | Improved | Not Met | 40.11% | -0.14% | Declined | Not Met |
| Ambulatory Care Follow-up with a Provider within 14 Days of Inpatient Discharge (FPID) | 46.85% | 52.17% | 54.10% | 7.25% | Improved | Met | 50.96% | 4.11% | Improved | Not Met |
| Behavioral Health Measures | | | | | | | | | | |
| Antidepressant Medication Management (AMM) Effective Acute Phase Treatment | 52.05% | 56.85% | 55.44% | 3.39% | Improved | Not Met | 49.31% | -2.74% | Declined | Not Met |
| Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment | 41.52% | 47.37% | 47.67% | 6.15% | Improved | Met | 36.11% | -5.41% | Declined | Not Met |
| Utilization rates per 1,000 Member Months | | | | | | | | | | |
| Ambulatory Care - ED Visits per 1000 Member Months | 178.23 | 160.41 | 76.93 | (101.30) | Improved | Met | 80.55 | -97.68 | Improved | Met |

* The SPR measure required two years of continuous enrollment for members. Rates with fewer than 30 eligible cases are reported as NA

ICP Non-Pay for Performance -HEDIS 2013 1/1/2012 to 12/31/2012

| Measure | State Baseline Rate | QISMC Goal | Aetna | | | | Illinicare | | | |
|--|---------------------|------------|------------|--------------------------|----------------|-------------------|------------------|--------------------------|----------------|-------------------|
| | | | Aetna Rate | Difference from Baseline | Overall Result | QISMC Goal Status | IlliniCare Rate | Difference from Baseline | Overall Result | QISMC Goal Status |
| Access to Care Measures (percentages) | | | | | | | | | | |
| Annual Dental Visit (ADV) | 23.92% | 31.53% | 23.15% | -0.77% | Declined | Not Met | 20.47% | -3.45% | Declined | Not Met |
| Inpatient Hospital 30-Day Readmission Rate (IPR) | 8.31% | 7.48% | 7.91% | -0.40% | Improved | Not Met | 12.82% | 4.51% | Declined | Not Met |
| Inpatient Mental Hospital 30-Day Readmission Rate (IMR) | 24.20% | 21.78% | 23.34% | -0.86% | Improved | Not Met | 27.61% | 3.41% | Declined | Not Met |
| Preventative Care Measures (percentages) | | | | | | | | | | |
| Influenza Immunization (FLU) | 9.92% | 18.93% | 13.08% | 3.16% | Improved | Not Met | 10.72% | 0.80% | Improved | Not Met |
| Cervical Cancer Screening (CCS) | 40.81% | 46.73% | 31.87% | -8.94% | Declined | Not Met | 37.55% | -3.26% | Declined | Not Met |
| Appropriate Care Measures (percentages) | | | | | | | | | | |
| Annual Monitoring for Patients on Persistent Medications (MPM) ACE Inhibitors or ARBs | 86.00% | 87.40% | 89.59% | 3.59% | Improved | Met | 89.21% | 3.21% | Improved | Met |
| Annual Monitoring for Patients on Persistent Medications (MPM) Digoxin | 81.46% | 83.31% | 94.04% | 12.58% | Improved | Met | 91.61% | 10.15% | Improved | Met |
| Annual Monitoring for Patients on Persistent Medications (MPM) Diuretics | 86.60% | 87.94% | 89.38% | 2.78% | Improved | Met | 89.66% | 3.06% | Improved | Met |
| Annual Monitoring for Patients on Persistent Medications (MPM) Anti-convulsants | 74.49% | 77.04% | 80.72% | 6.23% | Improved | Met | 78.77% | 4.28% | Improved | Met |
| Annual Monitoring for Patients on Persistent Medications (MPM) Total | 84.12% | 85.71% | 87.84% | 3.72% | Improved | Met | 87.67% | 3.55% | Improved | Met |
| Comprehensive Diabetes Care (CDC) - Hemoglobin A1c (HbA1c) Testing - DD Population Only | 79.05% | 81.15% | 80.26% | 1.21% | Improved | Not Met | 79.03% | -0.02% | Declined | Not Met |
| Behavioral Health Measures (percentages) | | | | | | | | | | |
| Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) | NA | NA | 80.89% | NA | NA | NA | 70.97% | NA | NA | NA |
| Behavioral Health Risk Assessment (BHRA) and Completed Within 60 Days of Enrollment* | NA | NA | 24.89% | NA | NA | NA | 27.70% | NA | NA | NA |
| Follow-up Completed within 30 Days of Positive BHRA* | NA | NA | 29.41% | NA | NA | NA | 38.77% | NA | NA | NA |
| Initiation and Engagement of AOD Dependence Treatment (IET) 18+ years - Initiation of AOD Treatment | 45.71% | 51.14% | 51.53% | 5.82% | Improved | Met | 53.56% | 7.85% | Improved | Met |
| Initiation and Engagement of AOD Dependence Treatment (IET) 18+ years - Engagement of AOD Treatment | 8.97% | 18.07% | 6.12% | -2.85% | Declined | Not Met | 5.00% | -3.97% | Declined | Not Met |
| Follow-Up After Hospitalization for Mental Illness (FUH) - 7-Day follow up | 34.67% | 41.20% | 25.93% | -8.74% | Declined | Not Met | 23.03% | -11.64% | Declined | Not Met |
| Utilization Measures (Per 1,000 Member Months) | | | | | | | | | | |
| Ambulatory Care (AMB) - ED Visits Per 1,000 MM (DD Population Only) | 112.06 | 100.85 | 46.36 | -65.70 | Improved | Met | Rate Unavailable | Rate Unavailable | NA | NA |
| Dental ED Visits Per 1,000 MM (DERV) | 11.37 | 10.23 | 0.80 | -10.57 | Improved | Met | 0.73 | -10.64 | Improved | Met |
| Inpatient Utilization (Per 1,000 Member Months) | | | | | | | | | | |
| Inpatient Utilization (IPU) - Genreal Hospital/Acute Care: Total Inpatient Discharges (Per 1,000 MM) | 40.35 | 36.32 | 27.65 | -12.70 | Improved | Met | 27.32 | -13.03 | Improved | Met |
| Inpatient Utilization (IPU) - Genreal Hospital/Acute Care: Total Medical Discharges (Per 1,000 MM) | 28.95 | 26.06 | 19.34 | -9.61 | Improved | Met | 19.29 | -9.66 | Improved | Met |
| Inpatient Utilization (IPU) - Genreal Hospital/Acute Care: Total Surgery Discharges (Per 1,000 MM) | 10.78 | 9.70 | 7.79 | -2.99 | Improved | Met | 7.61 | -3.17 | Improved | Met |
| Mental Health Utilization Inpatient and Outpatient Utilization (percentages) | | | | | | | | | | |
| Mental Health Utilization (MPT) Any Services Total | 25.04% | NA | 22.92% | -2.12% | NA | NA | 16.84% | -8.20% | NA | NA |
| Mental Health Utilization (MPT) Inpatient Total | 6.11% | NA | 5.62% | -0.49% | NA | NA | 4.20% | -1.91% | NA | NA |
| Mental Health Utilization (MPT) Intensive outpatient/partial Hospitalization Total | 2.74% | NA | 0.24% | -2.50% | NA | NA | 0.12% | -2.62% | NA | NA |
| Mental Health Utilization (MPT) Outpatient Total | 23.32% | NA | 21.03% | -2.29% | NA | NA | 15.19% | -8.13% | NA | NA |
| Long Term Care (Per 1,000 Member Months) | | | | | | | | | | |
| Long Term Care Urinary Tract Infection Admission Rate (UTI) | 2.17 | 1.95 | 0.42 | -1.75 | Improved | Met | 0.48 | -1.69 | Improved | Met |
| Long Term Care Bacterial Pneumonia Infection Admission Rate (BPAR) | 2.42 | 2.18 | 0.76 | -1.66 | Improved | Met | 0.83 | -1.59 | Improved | Met |

* There were no baseline rates established for the Behavioral Health Risk Assessment (BHRA) because the FFS did not collect this measure. The rates for this reporting period will be used to establish the baseline rates.